A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Latest Information Update: 07 Mar 2026
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms PILLAR
- Sponsors Novo Nordisk
Most Recent Events
- 07 Mar 2026 Last checked against ClinicalTrials.gov record.
- 24 Feb 2026 Planned End Date changed from 25 Oct 2027 to 15 Aug 2028.
- 24 Feb 2026 Planned primary completion date changed from 25 Oct 2027 to 15 Aug 2028.